Disposition of tradable shares by Kjellson Nina S of Tyra Biosciences at 17.1594 subject to Rule 16b-3
TYRA Stock | USD 15.68 0.32 2.00% |
About 56% of Tyra Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Tyra Biosciences suggests that many traders are alarmed. The current market sentiment, together with Tyra Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Tyra Biosciences stock news signals to limit their universe of possible portfolio assets.
Tyra |
Filed transaction by Tyra Biosciences Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at gurufocus.com
Tyra Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tyra Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tyra Biosciences Fundamental Analysis
We analyze Tyra Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tyra Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tyra Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Tyra Biosciences is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Tyra Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tyra Biosciences stock to make a market-neutral strategy. Peer analysis of Tyra Biosciences could also be used in its relative valuation, which is a method of valuing Tyra Biosciences by comparing valuation metrics with similar companies.
Peers
Tyra Biosciences Related Equities
GLUE | Monte Rosa | 13.72 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
XLO | Xilio Development | 7.92 | ||||
IPSC | Century Therapeutics | 5.52 | ||||
CNTB | Connect Biopharma | 2.91 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
RAPT | RAPT Therapeutics | 2.44 | ||||
IKNA | Ikena Oncology | 2.37 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
HOWL | Werewolf Therapeutics | 1.52 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
DSGN | Design Therapeutics | 0.50 | ||||
MOLN | Molecular Partners | 0.17 | ||||
ERAS | Erasca | 2.05 | ||||
PHVS | Pharvaris | 2.06 | ||||
MLYS | Mineralys Therapeutics, | 2.59 |
Complementary Tools for Tyra Stock analysis
When running Tyra Biosciences' price analysis, check to measure Tyra Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tyra Biosciences is operating at the current time. Most of Tyra Biosciences' value examination focuses on studying past and present price action to predict the probability of Tyra Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tyra Biosciences' price. Additionally, you may evaluate how the addition of Tyra Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |